The
Preclinical Imaging Market Size was valued at USD 4.4 billion in 2022 and is
projected to grow from USD 4.54 Billion in 2023 to USD 5.48 billion by 2030,
exhibiting a compound annual growth rate (CAGR) of 3.20% during the forecast
period (2023 - 2030).
The
preclinical imaging market is experiencing steady growth driven by
increasing R&D investments in pharmaceuticals and biotechnology. Expected
to reach $1.6 billion by 2027, the market is propelled by technological
advancements in imaging modalities such as MRI, CT, PET, and optical imaging.
Rising demand for non-invasive techniques for disease diagnosis and treatment
evaluation fuels market expansion. Moreover, the surge in chronic diseases like
cancer and cardiovascular disorders intensifies the need for accurate
preclinical research tools. North America dominates the market due to
substantial funding and a robust healthcare infrastructure. However,
Asia-Pacific showcases significant growth potential attributed to expanding
research activities and healthcare investments.
The
Preclinical Imaging Market is experiencing significant growth, driven by
advancements in technologies such as preclinical PET imaging and molecular
imaging. These cutting-edge techniques offer researchers unparalleled insights
into biological processes at the molecular level, revolutionizing drug
discovery and development.
Preclinical
PET imaging, a cornerstone of molecular imaging, enables scientists to
visualize and quantify molecular processes in living organisms. By employing
radiotracers tagged to specific molecules, researchers can track physiological
changes, disease progression, and treatment responses with remarkable
precision. This non-invasive modality expedites the evaluation of novel
therapeutics, enhances target identification, and improves the understanding of
disease mechanisms.
Molecular imaging techniques, including PET, SPECT, MRI, and
optical imaging, empower researchers to investigate cellular pathways, protein
interactions, and gene expressions in real-time. The integration of multimodal
imaging platforms enhances data accuracy and facilitates comprehensive
analysis, bolstering translational research efforts.
The
expanding applications of preclinical imaging across oncology, neuroscience,
cardiology, and other fields underscore its pivotal role in advancing
biomedical research. As pharmaceutical companies, academic institutions, and
contract research organizations increasingly recognize the value of preclinical
imaging, the market continues to burgeon.
Segmental
Analysis
The
global preclinical imaging market has been analyzed based on the reagent,
modality, and region.
The
modality-based segmentation of the market comprises into optical imaging
systems, nuclear imaging systems, micro-ultrasound, micro-MRI, photoacoustic
imaging, micro-CT, and magnetic particle imaging. The field of optical imaging
systems is predicted to continue its dominance over the market share as it
recorded in 2017.
The
reagent-based segmentation of the market comprises preclinical ultrasonic
contrast agents, preclinical optical imaging reagents, preclinical MRI contrast
agents, preclinical nuclear imaging reagents, and preclinical CT contrast
agents. The field of preclinical optical imaging reagents is predicted to
maintain its winning streak over the prognosis period.
Competitive
Dashboard
The
global preclinical imaging Companies are Bruker Corporation (US), MR Solutions
(UK), PerkinElmer Inc. (US), Fujifilm Holdings Corporation (Japan), Milabs B.V.
(The Netherlands), Mediso Ltd. (Hungary), LI-COR, Inc. (US), Miltenyi Biotec
GmbH (Germany), Aspect Imaging (Israel), and Trifoil Imaging (US).
Regional
Overview
The
Asia-Pacific preclinical imaging market is consists of developing economies
like China, the Republic of Korea, India , Japan, Australia, and the rest of
the Asia-Pacific region. The Asia-Pacific region is slated to be the region
with the highest growth. the high demand for remote sensing services in various
applications, such as precision farming, 3D terrain model building, damage
evaluation, pipeline tracking, geohazard modeling, resource extraction, and
security and intelligence is leading the Asia Pacific region market to secure
the fastest CAGR.
Driven
by growing investments in numerous military and commercial satellite projects,
North America is second to the European market in the demand for remote sensing
satellites. The North American industry is powered primarily by an growing need
for remote sensing services in diverse industries and the presence of major
public and private companies.
Europe
is slated to hold the second-largest regional growth in the global market for
preclinical imaging. The growing success of this region's demand is resulting
in further R&D investments towards the promotion of preclinical research.
On the other hand, the Middle East & Africa is observing gradual growth and
is slated to acquire for the lowest market share of the preclinical imaging
market.
Related
Reports
Hybrid Operating Room
Americas Gastrointestinal Drug
Healthcare Revenue Cycle Management
Vagal Nerve Stimulation
Allergy Skin Test
For More Information, Please Visit @ Market
Research Future
Comments
Post a Comment